Shares of Amneal Pharmaceuticals (NYSE:AMRX) moved higher by 13% in pre-market trading after the company reported Q1 results.
Earnings per share rose 42.86% year over year to $0.20, which beat the estimate of $0.09.
Revenue of $498,533,000 rose by 11.75% from the same period last year, which beat the estimate of $444,230,000.
Amneal Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: May 11, 2020
Time: 08:00 PM ET
Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Finvestors.amneal.com%2Fevents-and-presentations%2Fdefault.aspx&eventid=2160261&sessionid=1&key=E914BD59C23EF549366ECD92AF31432F®Tag=&sourcepage=register
Company's 52-week high was at $13.66
Company's 52-week low was at $2.27
Price action over last quarter: Up 7.39%
Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.